Ira Shoulson
#142,743
Most Influential Person Now
Ira Shoulson's AcademicInfluence.com Rankings
Ira Shoulsonphilosophy Degrees
Philosophy
#7523
World Rank
#10747
Historical Rank
Logic
#4576
World Rank
#5886
Historical Rank
Ira Shoulsonbiology Degrees
Biology
#10191
World Rank
#13498
Historical Rank
Neuroscience
#1557
World Rank
#1608
Historical Rank
Download Badge
Philosophy Biology
Why Is Ira Shoulson Influential?
(Suggest an Edit or Addition)Ira Shoulson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A polymorphic DNA marker genetically linked to Huntington's disease (1983) (2260)
- Levodopa and the progression of Parkinson's disease. (2004) (1676)
- Unified Huntington's disease rating scale: Reliability and consistency (1996) (1393)
- Variable expression of Parkinson's disease (1990) (1167)
- Trinucleotide repeat length instability and age of onset in Huntington's disease (1993) (1083)
- Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. (2002) (975)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000) (921)
- Effect of deprenyl on the progression of disability in early Parkinson's disease. (1989) (886)
- Detection of Huntington’s disease decades before diagnosis: the Predict-HD study (2007) (741)
- Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. (2004) (713)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
- Huntington disease (1979) (568)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease (2015) (420)
- NMDA receptor losses in putamen from patients with Huntington's disease. (1988) (408)
- Homozygotes for Huntington's disease (1987) (372)
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa (1996) (356)
- Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. (1985) (348)
- Rate of functional decline in Huntington’s disease (2000) (332)
- Urate as a predictor of the rate of clinical decline in Parkinson disease. (2009) (324)
- Preparing for preventive clinical trials: the Predict-HD study. (2006) (308)
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
- Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. (2008) (289)
- Weight loss in early stage of Huntington’s disease (2002) (284)
- Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
- Psychiatric syndromes in Huntington's disease. (1983) (257)
- Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
- Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. (2003) (246)
- CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset (2019) (236)
- Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease (1988) (234)
- On‐off response (1975) (232)
- Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals (1990) (231)
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions (2008) (226)
- Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial (2002) (212)
- Clinical markers of early disease in persons near onset of Huntington’s disease (2001) (207)
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (205)
- Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children (1999) (198)
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's (2016) (196)
- A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease (1994) (194)
- Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. (2007) (193)
- DATATOP: A decade of neuroprotective inquiry (1998) (179)
- Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility (1988) (176)
- Huntington disease (1981) (175)
- A controlled neuropsychological comparison of Huntington's disease and multiple sclerosis. (1986) (165)
- Huntington's disease in Venezuela (1986) (161)
- Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations (1986) (151)
- DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. (1998) (150)
- Longitudinal follow-up of SWEDD subjects in the PRECEPT Study (2014) (139)
- Limited Life Expectancy, Human Capital and Health Investments. (2013) (139)
- Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease (2011) (137)
- Predictors of nursing home placement in Huntington disease (2003) (132)
- A prospective evaluation of cognitive decline in early Huntington's disease (1995) (129)
- Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
- Altered cholesterol and fatty acid metabolism in Huntington disease. (2010) (120)
- Verbal episodic memory declines prior to diagnosis in Huntington's disease (2007) (119)
- Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum. (2013) (116)
- Clinical‐pathologic correlation in Huntington's disease (1989) (115)
- Cognitive Rehabilitation Therapy for Traumatic Brain Injury: Evaluating the Evidence (2013) (112)
- A controlled trial of remacemide hydrochloride in Huntington's disease (1996) (111)
- Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease (2012) (110)
- Huntington's disease (1976) (109)
- Duodenal and gastric delivery of levodopa in parkinsonism (1988) (108)
- Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia (1988) (106)
- Assessment of coenzyme q10 tolerability in huntington's disease (1996) (105)
- Natural history of Huntington disease. (2013) (103)
- Functional decline in Huntington's disease (1995) (103)
- The relationship between CAG repeat length and clinical progression in Huntington's disease (2008) (100)
- A controlled clinical trial of baclofen as protective therapy in early huntington's disease (1989) (100)
- Bromocriptine inhibits norepinephrine release (1979) (92)
- A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
- Heterogeneous dopamine receptor changes in early and late Huntington's disease (1991) (92)
- Huntington'S disease: Treatment with muscimol, A GABA‐mimetic drug (1978) (88)
- Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects (2010) (87)
- Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments (2006) (86)
- Norepinephrine in cerebrospinal fluid (1976) (85)
- Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (85)
- Experimental therapeutics of neurodegenerative disorders: unmet needs. (1998) (84)
- Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS (2013) (82)
- Benzodiazepine and GABA receptors in early Huntington's disease (1984) (82)
- Neuroleptic malignant syndrome. (1984) (82)
- Mendelian randomization of serum urate and parkinson disease progression (2014) (76)
- Interrater agreement in the assessment of motor manifestations of Huntington's disease (2005) (76)
- Dietary intake in adults at risk for Huntington disease (2009) (74)
- Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline (2006) (74)
- Toward more efficient clinical trials for amyotrophic lateral sclerosis (2010) (74)
- Milestones in Huntington disease (2011) (72)
- A controlled trial of fluoxetine in nondepressed patients with Huntington's disease (1997) (69)
- [Therapeutic strategies in Parkinson's disease]. (1991) (67)
- Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. (2008) (67)
- Rasagiline improves quality of life in patients with early Parkinson's disease (2006) (66)
- Severity of Tourette's syndrome in one large kindred. Implication for determination of disease prevalence rate. (1987) (66)
- Neural transplantation: a call for patience rather than patients. (1988) (65)
- The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease (1994) (61)
- A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
- A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III) (2017) (60)
- Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease (2009) (60)
- Huntington's disease. (1975) (60)
- Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. (2015) (60)
- Dementia in Huntington disease: a cross-sectional analysis of intellectual decline. (1983) (55)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
- A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. (2017) (51)
- A longitudinal program for biomarker development in Parkinson's disease: A feasibility study (2009) (50)
- Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease (2021) (49)
- Perception, experience, and response to genetic discrimination in Huntington disease: The international RESPOND‐HD study (2010) (49)
- In their own words: Reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND‐HD study (2010) (47)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- Safety of rasagiline in elderly patients with Parkinson disease (2006) (45)
- Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. (2009) (45)
- Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms (2006) (44)
- Controlled trial of propranolol in intermittent claudication (1975) (43)
- Studies with bromocriptine (1976) (43)
- HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD) (2016) (41)
- Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments (2013) (41)
- Serum urate and probability of dopaminergic deficit in early “Parkinson's disease” (2011) (40)
- Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. (2013) (40)
- Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations (1978) (40)
- Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) (1989) (39)
- An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (1992) (39)
- Cerebrospinal fluid correlates of depression in Huntington's disease. (1988) (38)
- Fear of health insurance loss among individuals at risk for Huntington disease (2008) (37)
- Myoclonus and dystonia: a family study. (1988) (37)
- Carbamazepine-induced tics. (1989) (37)
- Care of patients and families with Huntington's disease (1981) (36)
- On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. (1983) (36)
- A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. (1994) (35)
- Approaches and costs for sharing clinical research data. (2014) (35)
- Deep Phenotyping of Parkinson’s Disease (2020) (32)
- Studies with bromocriptine Part 2. Double‐blind comparison with levodopa in idiopathic parkinsonism (1976) (32)
- Huntington's disease. A decade of progress. (1984) (31)
- Coexistence of Huntington’s disease and familial amyotrophic lateral sclerosis: case presentation (1996) (30)
- Reversal of systemic manifestations of cryoglobulinemia. Treatment with melphalan and prednisone. (1976) (30)
- Communicating clinical trial results to research participants. (2008) (29)
- A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. (2006) (29)
- Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage (2007) (29)
- Long‐term experience with pergolide therapy of advanced parkinsonism (1985) (26)
- Dopaminergic mechanisms in patients with extrapyramidal disease. (1975) (24)
- Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease (2010) (24)
- Huntington's disease in Venezuela: Neurologic features and functional decline (2011) (24)
- Experimental therapeutics of movement disorders. (1983) (22)
- Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease (1988) (22)
- HUNTINGTON'S CHOREA TREATED WITH LITHIUM CARBONATE (1974) (21)
- Huntington’s Disease: Anti-Neurotoxic Therapeutic Strategies (1983) (21)
- Clonidine and the anti-parkinsonian response to l-dopa or piribedil (1976) (21)
- Selected health and lifestyle factors, cytosine‐adenine‐guanine status, and phenoconversion in Huntington's disease (2018) (21)
- Spinal myoclonus related to an arteriovenous malformation. Response to clonazepam therapy. (1983) (20)
- Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington’s Disease (2019) (20)
- TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. (2012) (20)
- Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? (1987) (20)
- Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum (2016) (19)
- Dystonia in central pontine myelinolysis without evidence of extrapontine myelinolysis. (1993) (19)
- An ergot derivative in the treatment of Parkinson's disease. (1976) (19)
- Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease (1989) (19)
- Where do we stand on neuroprotection? Where do we go from here? (1998) (19)
- Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts (2011) (18)
- Differential diagnosis of facial chorea. (1988) (18)
- Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience (2020) (18)
- Fenfluramine in man: hypophagia associated with diminished serotonin turnover. (1975) (18)
- Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease (2013) (17)
- Quantitative longitudinal assessment of saccades in Huntington's disease. (1993) (15)
- Cerebrospinal fluid norepinephrine reductions in man after degeneration and electrical stimulation of the caudate nucleus (1977) (15)
- Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. (2013) (14)
- Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine (2013) (14)
- Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study (2011) (14)
- Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at‐risk observational study (PHAROS) (2017) (14)
- A practical approach to remote longitudinal follow‐up of Parkinson's disease: The FOUND study (2014) (14)
- We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? (2002) (14)
- Clinical research in neurology. From observation to experimentation. (1996) (13)
- Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease. (2016) (13)
- Double‐blind assessment of potential pergolide‐induced cardiotoxicity (1986) (13)
- Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person (2020) (13)
- Some therapeutic observations in Wilson's disease. (1983) (12)
- Neurodegenerative Disorders and Aging Alzheimer's Disease and Parkinson's Disease – Common Ground a (1988) (12)
- Neuroprotective clinical strategies for Parkinson's disease (1992) (11)
- Huntington's disease: treatment with muscimol, a GABA-mimetic drug. (1977) (11)
- A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts (2009) (11)
- Letter: Huntington's disease: treatment with imidazole-4-acetic acid. (1975) (10)
- Advancing the Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation: A Summary Report of the Patient Preference Workshop (2019) (10)
- The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study (2019) (10)
- HTRF analysis of soluble huntingtin in PHAROS PBMCs (2013) (10)
- A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease (2017) (10)
- Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases (2017) (10)
- Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. (2012) (10)
- Preempting genetic discrimination and assaults on privacy: Report of a symposium (2003) (10)
- Up and down regulation: clinical significance of nervous system receptor-drug interactions. (1982) (9)
- Behavioural and biochemical effects of fenfluramine in patients with neurologic disease. (1975) (9)
- Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD) (2020) (9)
- Norepinephrine reductions in cerebrospinal fluid in man after electrical stimulation and degeneration of the caudate nucleus. (1976) (9)
- CEP-1347 Treatment Fails to Favorably Modify the Progression of Parkinson's Disease (PRECEPT) Study (2006) (9)
- Severe compression neuropathy following sudden onset of parkinsonian immobility. (1985) (9)
- Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea. (1976) (8)
- Juvenile-onset huntington disease: a matter of perspective. (2007) (8)
- Genetic modifiers of Huntington's disease differentially influence motor and cognitive domains (2022) (8)
- Using genome-Wwide complex trait analysis to quantify 'missing heritability' in Parkinson's disease (2012) (8)
- Informativeness of Early Huntington Disease Signs about Gene Status. (2015) (7)
- Regression of Striatal Dendrites in Parkinson’s Disease (1987) (7)
- From Observation to Experimentation (1996) (7)
- Therapeutic directions for Parkinson's disease (2010) (7)
- Measuring the effects of therapy in Parkinson disease. (2004) (7)
- Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia. (1983) (7)
- High-dosage vitamin E supplementation and all-cause mortality. (2005) (7)
- Antioxidative Therapeutic Strategies for Parkinson's Disease a (1992) (7)
- Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials (2020) (6)
- Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease (1988) (6)
- Deprenyl for the treatment of early Parkinson's disease. (1990) (6)
- Selegiline and Parkinson's disease. Protective and symptomatic considerations. (1990) (5)
- Neurotherapeutics, evidence-based neurology, and clinical equipoise. (1999) (5)
- Serotonergic functions in man. (1976) (5)
- Experimental neurotherapeutics: leaps and bounds. (2002) (5)
- Tissue culture evidence for a circulating neurotoxin in Huntington's chorea (1987) (5)
- I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies. (2017) (5)
- The role of mitochondrial DNA in Huntington’s disease (2008) (4)
- Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials. (2019) (4)
- Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. (2015) (4)
- Appendix for “ Optimal Expectations and Limited Medical Testing ” (2012) (4)
- Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes. (2018) (3)
- Flow cytometric detection of lymphocyte alterations in Huntington's disease. (1985) (3)
- Chapter 25 - Clinical Features and Care (2010) (3)
- Early‐stage Parkinson's disease: To treat or not to treat (1994) (3)
- Reexamination of the TEMPO Study—Reply (2005) (3)
- Data sharing for public health research: A qualitative study of industry and academia. (2015) (3)
- Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (3)
- Case 1, 1989: Juvenile‐onset parkinsonism, dystonia, and pyramidal tract signs (1989) (3)
- Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial. (2014) (3)
- Genetic overlap between psychiatric disorders and neuropsychiatric symptoms in HD (2019) (2)
- Developmental Chorea and Dystonia of Infancy (1987) (2)
- Treatment of Parkinson's disease with deprenyl (selegiline) and other monoamine oxidase inhibitors (1996) (2)
- On Chorea (1986) (2)
- Letter: Huntington's chorea treated with lithium carbonate. (1974) (2)
- Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group (2011) (2)
- Phenotype–genotype discrepancies in the prospective Huntington at‐risk observational study (2019) (2)
- Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting. (2020) (2)
- Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling (2021) (2)
- Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants. (2020) (2)
- Sociology of collaborative research groups (2004) (2)
- Influence of Insurance on the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington’s Disease (2008) (2)
- The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. (2019) (1)
- Measurement of caudate nucleus and putamen atrophy in patients with Huntington’s disease (1991) (1)
- PREDICT-HD: Markers Identifying Individuals at Risk for Huntington Disease (2001) (1)
- Harmonization of Drug Approval Guidelines in Alzheimer’s and Parkinson’s Diseases (1998) (1)
- Early Clinical Predictors of Treatment‐Resistant and Functional Outcomes in Parkinson's Disease (2016) (1)
- Selegiline and Parkinson’s Disease (1990) (1)
- Poster 6: Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease (2009) (1)
- Spinal Myoclonus Related to an Arteriovenous Malformation (2016) (1)
- In Memoriam: Robert J. Joynt, MD, PhD (1925-2012). (2012) (1)
- ·P-17 Investigator effects in a multicenter trial for parkinson's disease (1990) (1)
- Poster 21: Insurance Ownership and Genetic Risk (2009) (1)
- Mitochondrial haplogroups and cognitive progression in Parkinson's disease. (2022) (1)
- Communicating Findings to Research Participants: Preliminary Results from the TREND-HD Study (2008) (1)
- Excitotoxins and Hutington's disease (1987) (1)
- Amyotrophy and Huntingtonʼs Disease (HD): 128 (1995) (1)
- In memoriam (1999) (0)
- Reply: Unusual DAT scan results (2013) (0)
- Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases (2017) (0)
- Help 4 HD Symposium Connects HD Families and Medical Professionals with Leading HD Scientists, Researchers, and Advocates (2014) (0)
- Selected Health and Life Style Factors and Time to Phenoconversion in Huntington’s Disease (S47.003) (2014) (0)
- Does Mediterranean Diet Modify Phenoconversion in Huntington's Disease (HD) ? (P07.211) (2013) (0)
- Editorial Board (1991) (0)
- Pharmacotherapy use for non-motor symptoms among de novo Parkinson’s disease PPMI participants (2020) (0)
- COHORT: A Snapshot of Baseline Characteristics (2008) (0)
- Reply (1996) (0)
- J7 Intermediate allele expansion leads to huntington’s disease expression in large kindred (2016) (0)
- Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials (2022) (0)
- Second Annual Huntington Disease Clinical Research Symposium (2011) (0)
- ·P-64 Data top: Managing an accelerated trial (1990) (0)
- P28 Promoting enrollment in a multi-center clinical trial (1993) (0)
- Albright syndrome and leukemia. (1973) (0)
- Congresswoman Louise M. Slaughter (1929–2018) (2018) (0)
- NEUROLOGY NEEDS TO PREPARE FOR THE ‘FIRST GENOMIC’ CENTURY (2001) (0)
- O.085 Huntington disease (HD): clinical features and experimental therapeutics (2009) (0)
- Analysis of the Behavioral Features Conferred by the Intermediate Allele for Huntington Disease in the Prospective Huntington at Risk Observational Study (PHAROS) (PL01.003) (2012) (0)
- Subject file checklists to facilitate clinical trial close-out activities (1992) (0)
- The role of mitochondrial DNA in Huntington's disease (2008) (0)
- PHAROS: Phenoconversion to Manifest Huntington Disease (2001) (0)
- IN68-FR-02 CAG repeat disease mechanisms in Huntington disease (HD) (2009) (0)
- Use of computer applications to facilitate retroactive updates to a database (1991) (0)
- Editorial Board (2007) (0)
- 335P (1995) (0)
- Facilitating Medical Product Development Through Voluntary Data Sharing: A Look at the Legal Issues (2014) (0)
- 1.255 LONG-TERM EXPOSURE TO TETRABENAZINE (TBZ) HAS NO ADVERSE OR FAVORABLE IMPACT ON CHOREA AFTER IT IS WITHDRAWN (2012) (0)
- 335P Evaluation of the Glutamate Antagonist Remacemide Hydrochloride in Huntington's Disease (1995) (0)
- Reply (1999) (0)
- Acknowledgement to Referees (2014) (0)
- Reporting of randomized clinical trials and other population-based research: a priority of Archives of Neurology. (2004) (0)
- Hereditary Myoclonus and Chorea (1987) (0)
- Cerebrospinal Fluid Noradrenergic and Behavioral Alterations Associated with Stimulation and Atrophy of the Caudate Nucleus (1980) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ira Shoulson?
Ira Shoulson is affiliated with the following schools:
